Molecular signatures of EGFR-TKI sensitivity have recently been found in NSCLC: in particular, specific point mutations in the ATP pocket domain correlate with dramatic responses to gefitinib (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004). This evidence concerns the gene EGFR and non-small cell lung carcinoma.